

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

| | |
|-------------------|----------------------------------|
| Program Number | 2026 P 1431-3 |
| Program | Prior Authorization/Notification |
| Medication | Ogsiveo™ (nirogacestat) |
| P&T Approval Date | 1/2024, 1/2025, 1/2026 |
| Effective Date | 4/1/2026 |

1. Background:

Ogsiveo™ (nirogacestat) is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Coverage Information:

Members will be required to meet the criteria below for coverage. For members under the age of 19 years, the prescription will automatically process without a coverage review.

Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances. Some states also mandate usage of other Compendium references. Where such mandates apply, they supersede language in the benefit document or in the notification criteria.

2. Coverage Criteria^a:

| |
|--|
| <p>A. <u>Patients less than 19 years of age</u></p> <p>1. Ogsiveo will be approved based on the following criterion:</p> <p style="padding-left: 40px;">a. Patient is less than 19 years of age</p> <p style="text-align: center;">Authorization will be issued for 12 months.</p> <p>B. <u>Desmoid Tumors</u></p> <p>1. <u>Initial Authorization</u></p> <p>a. Ogsiveo will be approved based on all of the following criteria:</p> <p style="padding-left: 40px;">(1) Diagnosis of desmoid tumor</p> <p style="text-align: center;">-AND-</p> <p style="padding-left: 40px;">(2) Disease is progressive</p> <p style="text-align: center;">-AND-</p> <p style="padding-left: 40px;">(3) Patient requires systemic treatment</p> <p style="text-align: center;">Authorization will be issued for 12 months.</p> |
|--|

2. **Reauthorization Criteria**

a. **Ogsiveo** will be approved based on the following criterion:

- (1) Patient does not show evidence of progressive disease while on Ogsiveo therapy

Authorization will be issued for 12 months.

C. NCCN Recommended Regimens

The drug has been recognized for treatment of the cancer indication by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B

Authorization will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits and/or Step Therapy may be in place.

4. References:

1. Ogsiveo [package insert]. Stamford, CT: SpringWorks Therapeutics, Inc.; April 2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at https://www.nccn.org/professionals/drug_compendium/content/. Accessed November 24, 2025.

| Program | Prior Authorization/Notification - Ogsiveo (nirogacestat) |
|-----------------------|---|
| Change Control | |
| 1/2024 | New program. |
| 1/2025 | Annual review with no changes to coverage criteria. Updated references. |
| 1/2026 | Annual review with no changes to coverage criteria. Updated references. |